IL-12 Treatment of Naive CD8 T Cells for Stem Cell Memory Generation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for expanding and differentiating CD8 T cells for cancer immunotherapy overlook the molecular mechanisms governing CD8 T-cell differentiation, resulting in low levels of stem cell memory (Tscm) cells, which are crucial for effective tumor eradication, as traditional protocols fail to induce the desired epigenetic profiles in vitro-generated cells.
Innovation Solution
Exposing naïve CD8 T cells to signal 3 cytokines, such as IL-12, to induce phenotypic and epigenetic changes that mimic the characteristics of bona fide Tscm cells, enhancing their effector functions and proliferative capacity, thereby increasing the percentage of Tscm cells in the population.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If traditional differentiation protocols are used to expand CD8 T cells in vitro, then the T cell population can be generated for therapy, but the percentage of stem cell memory (Tscm) cells with desired epigenetic profiles remains low
Solution Approach 1:
The patent applies parameter changes by modifying cytokine concentrations and adding signal 3 cytokines (IL-12, IL-15, IL-21) to the culture medium to induce epigenetic changes. This transforms the differentiation process to generate Tscm cells with authentic epigenetic profiles, resolving the contradiction between quantity and manufacturing precision by changing the biochemical parameters of the culture system
Solution Approach 2:
The patent implements preliminary action by pre-treating naïve CD8 T cells with signal 3 cytokines before full differentiation. This preliminary exposure establishes the desired epigenetic profile early in the differentiation process, ensuring that subsequent expansion maintains the Tscm phenotype rather than allowing differentiation to proceed along traditional pathways that produce lower quality cells
2Quantity of substance
If signal 3 cytokines are used to induce epigenetic changes in CD8 T cells, then Tscm cell percentage increases, but the complexity of the culture protocol increases
Solution Approach 1:
The patent applies universality by using a combination of signal 3 cytokines (IL-12, IL-15, IL-21) that can be added to standard culture protocols. These cytokines serve multiple functions: they promote Tscm differentiation, maintain epigenetic profiles, and support cell survival and expansion. This multi-functionality allows the protocol to achieve complex epigenetic programming without requiring multiple separate treatment steps
Solution Approach 2:
The patent uses signal 3 cytokines as intermediaries that mediate between the culture conditions and the epigenetic state of T cells. Rather than directly manipulating epigenetic enzymes or chromatin structures, the cytokines serve as natural mediators that transmit signals to induce the desired epigenetic changes, simplifying the protocol compared to direct epigenetic editing approaches
3Reliability
If traditional protocols are used for CAR T cell generation, then production can proceed with existing methods, but the effector functions and proliferative capacity of generated cells are limited
Solution Approach 1:
The patent applies parameter changes by modifying the cytokine environment during CAR T cell production to include signal 3 cytokines. This changes the differentiation parameters to generate cells with enhanced effector functions and proliferative capacity. The parameter change affects both the quality (reliability) and functional output (productivity) of the final product without requiring fundamentally different production workflows
Solution Approach 2:
The patent implements preliminary action by exposing CD8 T cells to signal 3 cytokines before CAR transduction and during subsequent expansion. This preliminary epigenetic programming ensures that the CAR T cells develop enhanced effector functions and proliferative capacity from the outset, rather than attempting to improve these properties after differentiation is complete
Data Source
AI summary
Provided herein are methods and compositions for modulating T-cell activity by incubating a CD8 T cell with a signal 3 cytokine, such as IL-12. Incubation of naïve CD8 T cells, particularly, with a signal 3 cytokine can acquire long-lived memory associated gene expression characteristic of the stem cell memory subset of CD8 T cells. Further, incubation with signal 3 cytokines can induce changes to the epigenetic profile of naïve CD8 T cells that are more characteristic of bona fide Tscm cells than in vitro generated cells using traditional differentiation protocols. On account of epigenetic profiles being preserved during in vivo homeostasis, signal 3 cytokines such as IL-12 can be used to engineer a T cell population with the desired epigenetic profile that maintains effector functions and proliferative capacity.